Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Howell, Sacha J., Coe, Faye, Wang, Xin, Horsley, Laura, Ekholm, MariaJournal:
Breast Cancer Research and Treatment
DOI:
10.1007/s10549-020-05868-z
Date:
August, 2020
File:
PDF, 787 KB
2020